title: Cangrelor Bridge Therapy for Gastroduodenal Biopsy.
abstract: Dual antiplatelet therapy (DAPT) is the key for secondary prevention of acute coronary syndromes and percutaneous coronary intervention with stent placement. Premature discontinuation of DAPT can result in an increase in cardiac ischemic events and death. If early interruption of DAPT for urgent procedures or surgery is necessary, then ischemic and bleed risks must be balanced with bridging therapy. To date, no medications have a Food and Drug Administration indication for antiplatelet bridge therapy. We present a case of a woman with a history of gastrointestinal bleeding on DAPT for a drug-eluting stent who received cangrelor as bridge therapy prior to gastroduodenal biopsy.
authors.affiliation: 1 Department of Pharmacy, Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.|2 Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Cahoon
authors.affiliation: 1 Department of Pharmacy, Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.|2 Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
authors.forename: Allison K
authors.initials: AK
authors.lastname: Oswalt
authors.affiliation: 1 Department of Pharmacy, Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.|2 Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
authors.forename: Kerry E
authors.initials: KE
authors.lastname: Francis
authors.affiliation: 1 Department of Pharmacy, Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.|2 Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
authors.forename: Lauren C
authors.initials: LC
authors.lastname: Magee
authors.affiliation: 1 Department of Pharmacy, Virginia Commonwealth University Health System/Medical College of Virginia Hospitals, Richmond, VA, USA.|2 Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.
authors.forename: Denise K
authors.initials: DK
authors.lastname: Lowe
mesh_terms: D000249:Adenosine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D061605:Administration, Intravenous; D001706:Biopsy; D000077144:Clopidogrel; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000175:diagnosis*; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D010975:Platelet Aggregation Inhibitors; D000249:Adenosine Monophosphate; C117446:cangrelor; D000077144:Clopidogrel; D013988:Ticlopidine
keywords: antiplatelet; bridge; cangrelor; coronary stent